Entries by Organicell

MicroRNA Sequencing of Amniotic Fluid Derived Exosome Cargo Reveals a Therapeutic Potential for the Treatment of Osteoarthritis

M.A.Bellio1 Z.Abdullah1 D.Steward1 A.Khan2 X.Xu2 G.C.Shapiro1 A.Mitrani1 M.Mitrani11Organicell Regenerative Medicine Inc., Miami, Florida, United States2Assureimmune, LLC., Miami, Florida, United States Background & Aim Exosomes are being tested for their use as therapeutic agents in degenerative diseases such as Osteoarthritis (OA). However, the optimal source of exosomes is currently under investigation. Amniotic fluid (AF) is a […]

FDA Approves Two Emergency INDs to Administer Organicell Flow for COVID-19

FIRST PATIENTS TREATED WITH ORGANICELL FLOW THROUGH “EMERGENCY SINGLE PATIENT COMPASSIONATE USE” DESIGNATION Miami, FL (May 19, 2020) ­– Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that on May 11, 2020, the U.S. Food and Drug Administration (FDA) authorized two Emergency Compassionate Use Investigational […]

Organicell Announces FDA Approval of IND Application for the Treatment of SARS Due to COVID-19

Miami, FL (May 5, 2020) — Organicell Regenerative Medicine, Inc. (OTCBB:BPSR), a clinical-stage biopharmaceutical company dedicated to the development of regenerative therapies, announced today that the U.S. Food and Drug Administration (FDA) has approved the Investigational New Drug (IND) application for its lead product, Organicell Flow, for patients diagnosed with moderate to severe acute respiratory […]

Organicell Regenerative Medicine Inc. Provides Update On Operations and Financial Reporting Status

MIAMI, Jan. 21, 2020 (GLOBE NEWSWIRE) — Organicell Regenerative Medicine Inc.(OTCPK:BPSR) (the “Company”) is pleased to provide shareholders and the investment community with an update on operations. Since November 2018, the Company has remained focused on research and development activities and sale and distribution of anti-aging and cellular therapy derived products. In February 2019, the […]

Organicell Regenerative Medicine Inc., Biotech Products Services and Research, Inc. Update for Shareholders

Biotech Products Services and Research, Inc. operating as Organicell Regenerative Medicine Inc. (OTC: BPSR), today is providing its shareholders with an update on the Company’s progress. As previously announced, on April 23, 2018, Management and Business Associates, LLC, a company controlled by Mr. Manuel Iglesias, acquired 51% of the Company and Mr. Iglesias became our […]

Organicell Welcomes Dr. George C. Shapiro To The Medical Advisory Board

Biotech Products Services and Research, Inc. operating as Organicell Regenerative Medicine Inc. (OTC: BPSR), today announced the appointment of George C. Shapiro, M.D. F.A.C.C. to its medical advisory board. In addition to serving on the Company’s Advisory Board, Dr. Shapiro is assembling the medical advisory board for Organicell. Dr. Shapiro is a world-renowned cardiologist, a […]